BMYHealthcare · Drug Manufacturers - GeneralThe 28 Wall Street analysts covering Bristol Myers Squibb Co. hold a median 12-month price target of $68 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bristol Myers Squibb Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Accruals (65): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BMY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HSBC | Maintains | Hold | $60 → $65 |
| 5 Aug 2026 | Argus Research | Upgrade | Buy | $75 |
| 3 Aug 2026 | Citigroup | Maintains | Neutral | $66 → $70 |
| 31 July 2026 | Cantor Fitzgerald | Maintains | Neutral | $54 → $59 |
| 31 July 2026 | Guggenheim | Maintains | Buy | $72 → $75 |
| 31 July 2026 | JP Morgan | Maintains | Overweight | $67 → $73 |
| 31 July 2026 | RBC Capital | Maintains | Sector Perform | $60 → $64 |
| 31 July 2026 | Truist Securities | Reiterates | Buy | $65 → $70 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $60 → $65 |
| 10 July 2026 | B of A Securities | Maintains | Buy | — |
| 10 July 2026 | B of A Securities | Maintains | Buy | $67 → $66 |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 6 July 2026 | Cantor Fitzgerald | Reiterates | Neutral | $54 |
| 9 Apr 2026 | B of A Securities | Maintains | Buy | — |
| 8 Apr 2026 | Cantor Fitzgerald | Maintains | Neutral | — |
| 8 Apr 2026 | Guggenheim | Reiterates | Buy | — |
| 17 Mar 2026 | HSBC | Maintains | Hold | — |
| 25 Feb 2026 | RBC Capital | Initiates | Sector Perform | — |
| 23 Feb 2026 | Piper Sandler | Maintains | Overweight | — |
| 20 Feb 2026 | Barclays | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Bristol Myers Squibb Co. returned +40.2% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 45% of US stocks
Cheaper than 17% of US stocks
Cheaper than 43% of US stocks
Higher than 41% of US stocks
Higher than 88% of US stocks
Higher than 84% of US stocks
Higher than 89% of US stocks
Higher than 81% of US stocks
Higher than 92% of US stocks
Higher than 93% of US stocks
Higher than 76% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bristol Myers Squibb Co. has a market value of $130.0B and an enterprise value of $164.0B.
Revenue in the twelve months to 30 June 2026: $49.2B. The latest quarter grew 5.7% year on year.
Net income over the same four quarters: $9.3B, a 18.9% net margin.
Diluted earnings per share, trailing twelve months: $4.54.
Free cash flow in the twelve months to 30 June 2026: $11.4B, after $1.3B of capital spending.
Bristol Myers Squibb Co. spent $5.1B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 14.0×; forward P/E: 9.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 3.96%, paying out 55% of earnings.
Bristol Myers Squibb Co. employs 32,500 people — $1.5M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bristol Myers Squibb Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article discusses Bristol Myers Squibb's stock in the context of ongoing patent cliff concerns. It notes that management is taking active steps to counter these longstanding headwinds.
Why it matters — BMY watchers would care because it highlights the patent cliff pressures weighing on the company's stock and management's active efforts to address them.
The article explores how large a Bristol Myers Squibb position an investor would need to generate $10,000 per year in dividend income, working backward from that income target using the stock's current dividend yield. It frames the question as a straightforward calculation exercise for dividend-focused investors.
Why it matters — BMY watchers would care because it focuses on the company's dividend income potential, a key consideration for income-oriented shareholders evaluating the stock.
Bristol Myers Squibb (BMY) closed at $63.75 in the latest trading day, a -1.02% change from its previous close, reflecting a decline relative to the broader market.
Why it matters — BMY watchers would care because the stock's decline shows it underperforming the wider market on that trading day, which is relevant to tracking the company's recent price movement.
A Market Watch report discusses which stocks to favor and avoid in the fourth quarter, noting that large caps tend to outperform small caps as the year's end approaches. The article provides general seasonal market guidance rather than specific recommendations.
Why it matters — A BMY watcher would care because the article highlights a seasonal trend favoring large caps, a category that includes Bristol Myers Squibb, which could be relevant context heading into the final quarter.
The article reports that Bristol Myers Squibb shares have risen 19.4% year to date, driven by momentum from growth brands and pipeline progress. It also notes that generic competition pressure on the company's legacy portfolio warrants caution, framing the stock in a buy, sell, or hold context.
Why it matters — BMY watchers would want to weigh the tailwinds from growth products and pipeline developments against the ongoing erosion of older brands by generic competitors.
The 28 Wall Street analysts covering Bristol Myers Squibb Co. have a median 12-month price target of $68, with estimates ranging from $40 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Bristol Myers Squibb Co., 10 rate it a Buy, 17 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bristol Myers Squibb Co. 99 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Bristol Myers Squibb Co. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks Bristol Myers Squibb Co. 99 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bristol Myers Squibb Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $80 over the next 12 months.
Bristol Myers Squibb Co. returned +40.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions.
The most recent item we track (The Motley Fool, 13 Sept 2026): "Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?". The article discusses Bristol Myers Squibb's stock in the context of ongoing patent cliff concerns. It notes that management is taking active steps to counter these longstanding headwinds.
Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Bristol-Myers Squibb Company focuses on major therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, serving patients with complex and often chronic conditions. Its portfolio includes small-molecule drugs, biologics, and cell therapies, reflecting a broad approach to advanced treatment design and delivery. The company supports healthcare systems through research-driven products used in hospitals, specialty clinics, and outpatient care settings around the world. Bristol-Myers Squibb Company plays an important role in the pharmaceutical market by providing therapies aimed at difficult-to-treat illnesses and by maintaining a diversified pipeline and product mix across multiple disease categories.
CEO Dr. Christopher S. Boerner Ph.D. · 32,500 employees · United States · https://www.bms.com
